Corient Private Wealth LLC Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Corient Private Wealth LLC decreased its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 42.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 47,378 shares of the biopharmaceutical company's stock after selling 35,309 shares during the period. Corient Private Wealth LLC's holdings in TG Therapeutics were worth $1,426,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TGTX. Bleakley Financial Group LLC bought a new position in TG Therapeutics during the 4th quarter valued at approximately $245,000. Castellan Group bought a new stake in shares of TG Therapeutics during the 4th quarter valued at $8,539,000. Barclays PLC increased its stake in shares of TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after acquiring an additional 158,323 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock worth $16,859,000 after acquiring an additional 270,286 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new position in TG Therapeutics during the 3rd quarter valued at about $2,358,000. 58.58% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

Remove Ads

TG Therapeutics Stock Down 0.8 %

NASDAQ TGTX traded down $0.34 during mid-day trading on Friday, reaching $39.86. The stock had a trading volume of 1,642,962 shares, compared to its average volume of 3,069,404. The stock has a market cap of $6.26 billion, a PE ratio of -398.56 and a beta of 2.30. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $43.32. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company has a fifty day moving average price of $34.37 and a 200 day moving average price of $30.34.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. On average, research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the business's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.50% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.